These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 16832915)
1. Better protection for human subjects is outcome of very early clinical trials. Maloney DM Hum Res Rep; 2006 May; 21(5):1-2. PubMed ID: 16832915 [No Abstract] [Full Text] [Related]
2. The FDA clinical trial process: effectuating change in the regulatory framework governing clinical trials to account for the historical shift from "traditional" to "new" phase I trials. Aldes JL Health Matrix Clevel; 2008; 18(2):463-500. PubMed ID: 19739574 [No Abstract] [Full Text] [Related]
3. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Boyd RA; Lalonde RL Clin Pharmacol Ther; 2007 Jan; 81(1):24-6. PubMed ID: 17185993 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic orphans, pediatric victims? The Best Pharmaceuticals for Child Act and existing pediatric human subject protection. Cohen G Food Drug Law J; 2003; 58(4):661-710. PubMed ID: 15027456 [No Abstract] [Full Text] [Related]
5. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues. Rowland SS; Mayner RL; Barker L Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026 [TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trials: overcoming barriers. Bates SE Clin Cancer Res; 2010 Mar; 16(6):1709. PubMed ID: 20215552 [No Abstract] [Full Text] [Related]
7. FDA comments on phase I clinical trials without vector biodistribution data. Epstein S; Bauer S; Miller A; Pilaro A; Noguchi P Nat Genet; 1999 Aug; 22(4):326. PubMed ID: 10431234 [No Abstract] [Full Text] [Related]
12. Phase I cancer trials: therapeutic research? Kodish E Hastings Cent Rep; 2001; 31(1):4-5. PubMed ID: 11478093 [No Abstract] [Full Text] [Related]
13. Regulatory expectation for data on viral testing and process evaluation for phase I studies and product licensing in the United States, Europe and Japan. Dinowitz M; Sernatinger J; Wiebe M Dev Biol Stand; 1996; 88():148-51. PubMed ID: 9119128 [No Abstract] [Full Text] [Related]
14. Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule. Food and Drug Administration, HHS Fed Regist; 2008 Apr; 73(82):22800-16. PubMed ID: 18567164 [TBL] [Abstract][Full Text] [Related]
15. Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. White J; Parascandola M; Bero L Nicotine Tob Res; 2007 Nov; 9(11):1213-25. PubMed ID: 17978997 [TBL] [Abstract][Full Text] [Related]
16. Increasing participation of women in early phase clinical trials approved by the FDA. Pinnow E; Sharma P; Parekh A; Gevorkian N; Uhl K Womens Health Issues; 2009; 19(2):89-93. PubMed ID: 19272558 [TBL] [Abstract][Full Text] [Related]
17. Referral and decision making among advanced cancer patients participating in Phase I trials at a single institution. Gordon EJ; Daugherty CK J Clin Ethics; 2001; 12(1):31-8. PubMed ID: 11428154 [No Abstract] [Full Text] [Related]
18. Preclinical data expected for nucleotide GS 9219. AIDS Patient Care STDS; 2007 Apr; 21(4):289-90. PubMed ID: 17506142 [No Abstract] [Full Text] [Related]